Cargando…

Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions

Siglec-15, an inhibitory immune checkpoint, is an emerging target in cancer immunotherapy. Blocking the function of Siglec-15 is an excellent strategy for cancer treatment and antibody blockade has been used to target Siglec-15. However, whether Fc-mediated effector functions contribute to the thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Huandi, Yao, Bing, Ci, Lei, Feng, Jing, Ouyang, Pingkai, Chen, Guoguang, Hui, Xiwu, Zhou, Demin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Basic Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168116/ https://www.ncbi.nlm.nih.gov/pubmed/37103472 http://dx.doi.org/10.1097/CJI.0000000000000465

Ejemplares similares

Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China
por: Yao, Bing, et al.
Publicado: (2022)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020)

Fc-engineered antibodies with immune effector functions completely abolished
por: Wilkinson, Ian, et al.
Publicado: (2021)

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
por: Zhang, Di, et al.
Publicado: (2016)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
por: Liu, Rena, et al.
Publicado: (2020)

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors: Fc-mediated avidity enhances the potency of an anti-TLR4 antibody
por: Loyau, Jérémy, et al.
Publicado: (2014)

Expression of a Siglec-Fc Protein and Its Characterization
por: Chi, Kaijun, et al.
Publicado: (2023)

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy
por: Klausz, Katja, et al.
Publicado: (2020)

Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination
por: Nduati, Eunice W., et al.
Publicado: (2021)

Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations
por: Torgeman, Amram, et al.
Publicado: (2017)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

Boosting therapeutic potency of antibodies by taming Fc domain functions
por: Kang, Tae Hyun, et al.
Publicado: (2019)

High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy
por: He, Fei, et al.
Publicado: (2021)

Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022)

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
por: Heckel, Franziska, et al.
Publicado: (2022)

Vector induced skewing of antibody Fc-effector functions
por: Chung, A, et al.
Publicado: (2012)

Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2021)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
por: Schriek, Angela I., et al.
Publicado: (2022)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
por: Shubin, Zhanna, et al.
Publicado: (2023)

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
por: Schriek, Angela I., et al.
Publicado: (2022)

Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
por: Gunn, Bronwyn M., et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
por: Brown, Eric P., et al.
Publicado: (2017)

Monocyte Siglec-14 expression is upregulated in patients with systemic lupus erythematosus and correlates with lupus disease activity
por: Thornhill, Susannah I., et al.
Publicado: (2017)

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation
por: Rashid, Md Harunur
Publicado: (2022)

Structural characterization of a human Fc fragment engineered for lack of effector functions
por: Oganesyan, Vaheh, et al.
Publicado: (2008)

Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity
por: Choi, Hyeree, et al.
Publicado: (2021)

Siglec-15 promotes progression of clear renal cell carcinoma
por: Yang, Wen-Bo, et al.
Publicado: (2021)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Antibody engineering for increased potency, breadth and half-life
por: Sievers, Stuart A., et al.
Publicado: (2015)

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
por: Shiakolas, Andrea R., et al.
Publicado: (2021)

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
por: Golay, Josée, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ac9hp26gg0hs13h6cmo7kc3k0